Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Revive Therapeutics Ltd (RVVTF)

Revive Therapeutics Ltd (RVVTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure GlobeNewswire - Mon May 12, 1:07PM CDT

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics Announces Proposed Shares for Debt Transaction GlobeNewswire - Mon Apr 21, 3:30PM CDT

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment GlobeNewswire - Thu Apr 10, 6:00AM CDT

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program GlobeNewswire - Tue Apr 1, 6:30AM CDT

RVV.CN : 0.0250 (unch)
DMED.CN : 0.0350 (unch)
DGNMF : 0.0172 (-46.25%)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics Announces Results of Annual Shareholder Meeting GlobeNewswire - Wed Mar 19, 8:14AM CDT

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program GlobeNewswire - Mon Mar 3, 7:00AM CST

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures GlobeNewswire - Mon Feb 3, 4:00PM CST

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure GlobeNewswire - Wed Jan 8, 6:30AM CST

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke GlobeNewswire - Tue Nov 12, 2024

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure GlobeNewswire - Thu Oct 31, 2024

RVV.CN : 0.0250 (unch)
RVVTF : 0.0195 (+5.41%)

Barchart Exclusives

Is Intel Stock a Buy on Rumors of Networking Business Sale? Barchart - 22 minutes ago
Intel is moving away from underperforming businesses. Could selling its networking and edge unit improve INTC stock outlook? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot